KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for BeOne Medicines (ONC) over the last 11 years, with Q3 2025 value amounting to $2.4 billion.

  • BeOne Medicines' Total Current Liabilities rose 1694.01% to $2.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 billion, marking a year-over-year increase of 1694.01%. This contributed to the annual value of $2.2 billion for FY2024, which is 2236.25% up from last year.
  • Per BeOne Medicines' latest filing, its Total Current Liabilities stood at $2.4 billion for Q3 2025, which was up 1694.01% from $2.2 billion recorded in Q2 2025.
  • Over the past 5 years, BeOne Medicines' Total Current Liabilities peaked at $2.4 billion during Q3 2025, and registered a low of $917.4 million during Q4 2022.
  • Its 5-year average for Total Current Liabilities is $1.6 billion, with a median of $1.4 billion in 2022.
  • As far as peak fluctuations go, BeOne Medicines' Total Current Liabilities surged by 14624.82% in 2021, and later tumbled by 4264.95% in 2022.
  • Over the past 5 years, BeOne Medicines' Total Current Liabilities (Quarter) stood at $1.6 billion in 2021, then tumbled by 42.65% to $917.4 million in 2022, then skyrocketed by 97.32% to $1.8 billion in 2023, then increased by 22.36% to $2.2 billion in 2024, then increased by 6.93% to $2.4 billion in 2025.
  • Its last three reported values are $2.4 billion in Q3 2025, $2.2 billion for Q2 2025, and $2.0 billion during Q1 2025.